Exagen Inc. provided revenue guidance for the full year 2022. For the period, the company expects revenue to be in the range of $51 million to $53 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.88 USD | -0.53% | +19.75% | -5.53% |
05-14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
05-13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.53% | 32.63M | |
+19.28% | 84.56B | |
-26.95% | 72.41B | |
+4.58% | 27.75B | |
-7.35% | 17.75B | |
-0.46% | 17.11B | |
+4.69% | 16.03B | |
+8.14% | 13.72B | |
+69.96% | 13.07B | |
+6.59% | 12.91B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Provides Revenue Guidance for the Full Year 2022